Adc Therapeutics SA - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl). ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Headquartered in Lausanne (Biopôle), Switzerland, with operations in New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization.
No news available
Limited Time
Get premium stock ratings, research, analyst insights, and portfolio tools with a limited-time discount.
25% off Seeking Alpha Premium through July 7.
Claim 25% discountSponsored partner offer: The 25% Seeking Alpha Premium discount is available for a limited time. Terms apply.